country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P5985

Copy Link Print Information

mSIRK

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

mSIRK (G-Protein βγ Binding Peptide) is an cell-permeable activator of ERK1/2, with EC₅₀ of 2.5-5 μM. mSIRK disrupts the interaction between α and βγ subunits and promotes α subunit dissociation without stimulating nucleotide exchange.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.54%
CAS. Nr.: 593267-11-9
Formel: C₉₃H₁₅₀N₂₀O₂₅
Molecular Weight:1948.31

Speicherung:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

mSIRK Chemical Structure

CAS. Nr.: 593267-11-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle ERK Isoform-spezifische Produkte anzeigen :

In Vitro

mSIRK (1.2-30 μM, 1-30 min) can rapidly activate extracellular signal-regulated kinases 1/2, stimulates the phosphorylation of Jun N-terminal kinase, the phosphorylation of p38 mitogen-activated protein kinase and the activity of phospholipase C, and leads to the internal storage and release of Ca²⁺^[1].
mSIRK (10 μM, 24 h) rescues the inhibitory effect on cell proliferation and migration induced by Y27632 (HY-10071)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

RASM, ddtMF2, MDA, Rat2, HEK293, COS7
Concentration:

1.2, 2.5, 5, 10, 30 μM
Incubation Time:

1, 2, 5, 10, 15, 30 min
Result:

Led to rapid and dose-dependent activation of ERK1/2.
Reached full activation after 1 minute of application and weakens within 30 minutes.
The phosphorylation of p38 MAP kinase and Jun kinase increased.
The activation degree of ERK1/2 depends on the cell type.

Cell Viability Assay^[2]

Cell Line:

SCC9 cell
Concentration:

10 μM
Incubation Time:

24 h
Result:

Partially rescued the inhibitory effect on cell proliferation and migration induced by Y27632.

Chemical Information

CAS. Nr. 593267-11-9
Appearance Solid
Molecular Weight 1948.31
Formel C₉₃H₁₅₀N₂₀O₂₅
Color White to off-white
Sequence

{Myr}-Ser-Ile-Arg-Lys-Ala-Leu-Asn-Ile-Leu-Gly-Tyr-Pro-Asp-Tyr-Asp
Sequence Shortening

{Myr}-SIRKALNILGYPDYD
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (2)

All WBCell Proliferation/Viability AssayCell Migration/Invasion Assay

Sort by:

Journal Impact Factor

Int Immunopharmacol

Novel analgesic peptide derived from Cinobufacini injection suppressing inflammation and pain via ERK1/2/COX-2 pathway. [Abstract]

2024 Nov 15:141:112918. PMID: 39159558

mSIRK purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Nov 15:141:112918. [Abstract]

Western Blotting images of Rac-2, ERK 1/2, p-ERK 1/2 and COX-2 proteins in mSIRK (5 μM; 3 h then further co-cultured with CI5 for another 12 h) TFA-treated RAW264.7 macrophages treated with different concentration (100, 150 and 200 μg/mL) of CI5 for 12 h.
Oncologie

2024 Oct 11;26(6).

mSIRK purchased from MedChemExpress. Usage Cited in: Oncologie. 2024 Oct 11;26(6).

CCK8 was performed to detect the cell viability of SCC9 cells treated with Y27632, ERK/JNK inhibitors (mSIRK (10 μM), ect.) or in combination for 72 h.

mSIRK purchased from MedChemExpress. Usage Cited in: Oncologie. 2024 Oct 11;26(6).

Wound healing assay of cells with treatment of Y27632, ERK/JNK inhibitors (mSIRK (10 μM), ect.) or in combination. Scale bar: 20 μm.

mSIRK purchased from MedChemExpress. Usage Cited in: Oncologie. 2024 Oct 11;26(6).

Western blot analysis of indicated protein level in mutp53 SCC9 cells treated with Y27632, mSIRK (24 h) (ERK activator, 10 μM) or Anisomycin (JNK activator, 10 μM).

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (51.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.5133 mL

2.5663 mL

5.1327 mL

5 mM

0.1027 mL

0.5133 mL

1.0265 mL

10 mM

0.0513 mL

0.2566 mL

0.5133 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Farida Goubaeva, et al. Stimulation of Cellular Signaling and G Protein Subunit Dissociation by G Protein βγ Subunit-binding Peptides. J Biol Chem. 2003 May 30;278(22):19634-41. [Content Brief]

[2]. Zhang XL, et al. Y27632 induces tongue squamous cell carcinoma cell apoptosis through MAPK-ERK/JNK signal. De Gruyter Brill.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.5133 mL	2.5663 mL	5.1327 mL	12.8316 mL
	5 mM	0.1027 mL	0.5133 mL	1.0265 mL	2.5663 mL
	10 mM	0.0513 mL	0.2566 mL	0.5133 mL	1.2832 mL
	15 mM	0.0342 mL	0.1711 mL	0.3422 mL	0.8554 mL
	20 mM	0.0257 mL	0.1283 mL	0.2566 mL	0.6416 mL
	25 mM	0.0205 mL	0.1027 mL	0.2053 mL	0.5133 mL
	30 mM	0.0171 mL	0.0855 mL	0.1711 mL	0.4277 mL
	40 mM	0.0128 mL	0.0642 mL	0.1283 mL	0.3208 mL
	50 mM	0.0103 mL	0.0513 mL	0.1027 mL	0.2566 mL

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise

1/16
1/16

mSIRK purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Nov 15:141:112918. [Abstract]

Customer Validation
Western Blotting images of Rac-2, ERK 1/2, p-ERK 1/2 and COX-2 proteins in mSIRK (5 μM; 3 h then further co-cultured with CI5 for another 12 h) TFA-treated RAW264.7 macrophages treated with different concentration (100, 150 and 200 μg/mL) of CI5 for 12 h.
1/16

mSIRK purchased from MedChemExpress. Usage Cited in: Oncologie. 2024 Oct 11;26(6).

Customer Validation
CCK8 was performed to detect the cell viability of SCC9 cells treated with Y27632, ERK/JNK inhibitors (mSIRK (10 μM), ect.) or in combination for 72 h.
1/16

mSIRK purchased from MedChemExpress. Usage Cited in: Oncologie. 2024 Oct 11;26(6).

Customer Validation
Wound healing assay of cells with treatment of Y27632, ERK/JNK inhibitors (mSIRK (10 μM), ect.) or in combination. Scale bar: 20 μm.
1/16

mSIRK purchased from MedChemExpress. Usage Cited in: Oncologie. 2024 Oct 11;26(6).

Customer Validation
Western blot analysis of indicated protein level in mutp53 SCC9 cells treated with Y27632, mSIRK (24 h) (ERK activator, 10 μM) or Anisomycin (JNK activator, 10 μM).

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

mSIRK

Publications Citing Use of MedChemExpress (MCE) mSIRK

Alle ERK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

mSIRK Related Classifications

HY-P5985 Related Classifications